Fac­ing broad push­back from in­dus­try, White House backs down on FDA's Covid-19 vac­cine guid­ance

Fac­ing thin­ly-veiled crit­i­cism from the na­tion’s largest drug­mak­ing lob­by and a di­rect refu­ta­tion from the CEO of the lead­ing Covid-19 vac­cine de­vel­op­er, the White House has backed off of its ef­forts to block FDA guid­ance that would place stricter re­quire­ments for a coro­n­avirus vac­cine to win au­tho­riza­tion, sev­er­al out­lets re­port­ed.

The move like­ly means that Pfiz­er’s vac­cine will not meet the FDA’s stan­dards be­fore Elec­tion Day, as Pres­i­dent Don­ald Trump has re­peat­ed­ly promised over the ob­jec­tion of his own pub­lic health of­fi­cials and in­de­pen­dent ex­perts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER